Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer

European Journal of Cancer

Volumn 45, Issue 14, 2009, Pages 2444-2446

  Schmitt, Manfred ^a   Sweep, Fred C G J ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; COLORECTAL CANCER; HUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STOMACH CANCER; TUMOR GROWTH;

EID: 69249084556     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.07.001     Document Type: Note

References (16)

1. Tack D.K., Palmieri F.M., and Perez E.A. Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. Oncology 18 (2004) 1367-1376
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
3. Adjuvant Therapy for Breast Cancer, National Institutes of Health Consensus Development Conference Statement, November 1-3, 2000. .
4. Poole C.J., Earl H.M., Hiller L., et al., NEAT Investigators and the SCTBG. Epirubicine and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355 (2006) 1851-1862
5. Di Leo A., Gancberg D., Larsimont D., et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8 (2002) 1107-1116
6. Harris L., Fritsche H., Mennel R., et al., American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007) 5287-5312
7. Willemoe GL, Hertel PB, Bartels A, et al. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. Eur J Cancer [in this issue].
8. Duffy M.J., McGowan P.M., and Gallagher W.M. Cancer invasion and metastasis: changing views. J Pathol 214 (2008) 283-293
9. Schmitt M., Harbeck N., Thomssen C., et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78 (1997) 285-296
10. Stetler-Stevenson W.G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1 (2008) re6
11. Holten-Andersen M.N., Stephens R.W., Nielsen H.J., et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6 (2000) 4292-4299
12. Schrohl A.S., Meijer-van Gelder M.E., Holten-Andersen M.N., et al. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 12 (2006) 7054-7058
13. Davidsen M.L., Würtz S., Rømer M.U., et al. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95 (2006) 1114-1120
14. Ejlertsen B., Jensen M.B., Nielsen K.V., et al. TOP2A, TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients [abstract]. Cancer Res 69 Suppl. (2009) 72s
15. Tang S.C. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions. Cancer Invest 27 (2009) 489-495
16. Wurtz S.O., Schrohl A., Brünner N., and Lademann U. Tissue inhibitor of metalloproteinases-1 protects the human breast carcinoma cell line MCF-7 S1 against anthracycline-induced cell death by activation of the akt survival pathway [abstract]. Cancer Res 69 Suppl. (2009) 161s